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Abstract: CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor 
being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol. 
We investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single 
doses of CKD-519 in healthy adult subjects. A randomized, double-blinded, placebo-controlled, 
single ascending dose study was performed. Eight healthy subjects were enrolled in each 
CKD-519 dose group (25, 50, 100, 200, or 400 mg) and randomized to CKD-519 (n=6) or 
matching placebo (n=2). CKD-519 reached the maximum plasma concentration (C
max
) at 5–6 h 
post-dose, and had a long terminal half-life ranging between 40–70 h. The area under the plasma 
concentration–time curve (AUC) and C
max
 increased with the dose, however, C
max
 and AUC 
normalized by dose decreased with each incremental dose. CETP activity decreased with dose, 
and the maximum decrease (63%–83%) was observed at 6–8 h post-dose. A sigmoid E
max
 model 
best described the relationship between CKD-519 plasma concentrations and CETP activity 
with an EC
50
 of 17.3 ng/mL. Overall, 11 adverse events (AEs) were observed. All AEs were 
mild or moderate in intensity, and resolved without any complications. There were no clinically 
significant effects on blood pressure. In conclusion, single doses of CKD-519 up to 400 mg 
were well tolerated and showed potent inhibition of CETP activity.
Keywords: cholesteryl ester transfer protein inhibitor, CKD-519, pharmacokinetics, pharma-
codynamics
Introduction
Cardiovascular disease, the leading cause of mortality in the world, is closely related 
with dyslipidemia.1 Elevated low-density lipoprotein cholesterol (LDL-C) repre-
sents a major risk for cardiovascular events.2 LDL-C lowering has been and still is a 
primary target to prevent or reduce cardiovascular events.3 Although each decrease 
of 1.0 mmol/L in LDL-C with 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors (statins) has been reported to reduce major cardiovascular events by 24%, 
there remain some substantial residual cardiovascular risks.4 The decreasing level 
of high-density lipoprotein cholesterol (HDL-C) was associated with increasing 
frequency of major cardiovascular events.5 A low level of HDL-C is regarded as a 
strong risk factor of cardiovascular disease.6–8 Even in patients who maintain very 
low LDL-C level with statins, a low level of HDL-C is predictive of potential risk of 
cardiovascular disease.5,7
Based on these findings, raising HDL-C levels has become a potential target for 
reducing cardiovascular events. There are several approaches known to increase 
HDL-C. One is stimulation of production of apolipoprotein AI, the principal protein 
component of HDL-C, by fibrates, statins, or glitazones.9,10 However, there are 
several limitations to this approach using these therapeutic agents. The fibrates and 
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statin produce only modest elevations in HDL-C, and the 
use of them has been restricted by side effects.11,12 Another 
approach is HDL particles remodeling by inhibition of 
cholesteryl ester transfer protein (CETP).13 CETP is a gly-
coprotein that facilitates the transfer of cholesteryl esters and 
triglycerides from HDL-C to apolipoprotein B-containing 
lipoproteins, very low-density lipoprotein (VLDL), and 
LDL-C.14 According to this mechanism, CETP inhibition 
leads to HDL-C increase and LDL-C decrease as exhibited 
by a few CETP inhibitors.12,15 Several CETP inhibitors have 
failed to access the market, whereas others are still under 
development. Torcetrapib showed HDL-C increase and 
LDL-C decrease in the ILLUMINATE trial; however, the 
trial was stopped due to a significantly increased risk of 
death and cardiac events in patients receiving torcetrapib.16 
The increased mortality in the torcetrapib group could be 
a result of an off-target effect associated with changes in 
aldosterone and endhthelin-1 levels.17 Dalcetrapib did not 
demonstrate a significant reduction of cardiovascular events 
compared to placebo group, although it increased HDL-C 
levels.18 Evacetrapib also did not improve the efficacy in 
the phase 3 ACCELERATE trial. Therefore, the trial was 
stopped and the company discontinued development of the 
drug.19 Anacetrapib, the main CETP inhibitor, is still being 
evaluated. With not yet published results, the phase 3 double-
blind clinical trial (ClinicalTrials.gov unique identifier: 
NCT01252953) including 30,000 patients with circulatory 
problems is ongoing.20
CKD-519 (Chong Kun Dang Pharmaceutical Corp., 
Seoul, Korea) is a potent CETP inhibitor newly developed for 
the treatment of dyslipidemia (Figure 1). CKD-519 inhibits 
the CETP-mediated transfer of cholesteryl ester in human 
serum (IC
50
 2.3 nM).21 In nonclinical studies, CKD-519 
exhibited a maximum of 70%–86% inhibition of CETP 
activity and 25%–48% increase of HDL-C levels after two 
weeks of oral administration of 1, 3, or 10 mg/kg in trans-
genic mice expressing human CETP/apolipoprotein AI.21 
In other nonclinical studies, inhibitory activity of CKD-519 
was maintained until 48 h in dyslipidemic hamster model 
(IC
50
 31.4 nM) and 72 h (IC
50
 83 nM) in cynomolgus monkey 
after single administration of CKD-519 in the range from 
0.1 to 30 mg/kg (Chong Kun Dang Pharmaceutical Corp., 
unpublished data, 2015). The differences in in vitro and ex-
vivo IC
50
 values might have been resulted from high plasma 
protein binding capacity of CKD-519 (.99%).
This study is the first in-human study of CKD-519, and 
we evaluated the pharmacokinetics (PK), pharmacodynamics 
(PD), safety, and tolerability of CKD-519 in healthy adult 
individuals.
Materials and methods
ethics
The study protocol was approved by the Institutional Review 
Board of Severance Hospital, Yonsei University College of 
Medicine (Seoul, Korea), and conducted in accordance with 
the Declaration of Helsinki, the guidelines in the International 
Conference on Harmonization of Pharmaceuticals for Human 
Use-Good Clinical Practice and local regulations (IRB 
number: 4-2014-0113). All participants were enrolled in the 
study after obtaining written informed consent. This trial 
was registered with the identifier number NCT02156544 at 
ClinicalTrials.gov.
subjects
Korean healthy adult male volunteers aged 19–55 years 
with a body mass index between 18.5 and 25.0 kg/m2 (body 
weight [kg]/height [m]2) were enrolled in this study. Both 
genders were eligible in this study, however, only healthy 
male subjects were recruited. Each subject was screened by 
a medical history, physical examination, 12-lead electro-
cardiography (ECG), and laboratory tests. Volunteers with 
the following criteria were excluded: a medical history of 
diseases that might influence the PK or PD evaluation of 
the CKD-519, a history of clinically significant hypersen-
sitivity reaction to drugs or foods, systolic blood pressure 
(SBP) .150 mmHg or ,90 mmHg, diastolic blood pressure 
(DBP) .100 mmHg or ,50 mmHg, or positive results of 
urine drug screening for controlled substances (amphet-
amine, barbiturate, morphine, benzodiazepine, and cocaine) 
or serology test (hepatitis B surface antigen, anti-hepatitis 
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Figure 1 chemical structure of cKD-519.
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C virus antibody, and anti-HIV antibody). The participants 
were not permitted to take any drugs or herbal medications 
for two weeks prior to the treatment, nor any over-the-counter 
drugs or supplements for one week prior to the treatment. 
The participants were also restricted from consuming alcohol, 
caffeinated beverages, or grapefruit products, as well as from 
smoking during this study.
study design
A dose-block, randomized, double-blinded, placebo- 
controlled, single-dose, and dose-escalation study was con-
ducted in a total of 40 subjects in five cohorts (25, 50, 100, 
200, and 400 mg). Six individuals were randomly assigned to 
CKD-519 and two to matching placebo within each cohort. 
Starting with the lowest dose cohort, dose escalation to the 
next higher dose was proceeded after the safety profile of the 
dose was confirmed. CKD-519 was available in 25 mg and 
50 mg tablets. In the 50 mg cohort, CKD-519 50 mg was 
used in accordance with the cohort dose: 50 mg ×2 tablets 
for 100 mg cohort, 50 mg ×4 tablets for 200 mg cohort, and 
50 mg ×8 tablets for 400 mg cohort.
Enrolled subjects were admitted prior to dosing day. 
After overnight fasting, a single dose of CKD-519 or placebo 
with 240 mL water was administered to randomly assigned 
subjects. All subjects were denied drinking water before and 
after 1 h of dosing, and kept in fasted condition until 4 h 
post-dose of CKD-519 or placebo. Serial blood samples for 
PK were collected in sodium heparin tubes prior to dosing, 
and after 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 
72, 96, 120, 144, and 168 h. In addition, peripheral venous 
blood for PD was collected in sodium heparin tubes prior to 
dosing, and after 0.5, 1, 2, 4, 8, 18, 24, 48, 72, 96, 120, 144, 
and 168 h. Each blood sample for PK and PD was centri-
fuged at 1,900× g for 10 min, and aliquots were stored at or 
below −70°C until analysis.
safety assessment
Adverse events (AEs) were monitored throughout the study. 
All cohorts performed safety evaluations as follows: physical 
examinations, vital signs monitoring, 12-lead ECG, and 
laboratory tests including hematology, serum chemistry and 
urinalysis. SBP, DBP, and pulse rate were measured in a sit-
ting position before drug administration and at 2.5, 4.5, 6.5, 
8.5, 10.5, 12.5, 16.5, 20.5, 24.5, 32.5, 40.5, 48.5, 72.5, 96, 
120, 144, and 168 h after dosing and during a follow-up visit. 
Twelve-lead ECG was taken prior to dosing and at 4, 8, and 
72 h after dosing, and during a follow-up visit. Laboratory 
tests were done pre- and post-dosing.
Measurement of plasma cKD-519 
concentration
The plasma concentrations of CKD-519 were measured using 
a validated high performance liquid chromatography assay 
(Shiseido Nonospace SI-2; Shiseido, Tokyo, Japan) coupled 
with tandem mass spectrometry (MS/MS, 4000QTRAP; 
AB SCIEX, Framingham, MA, USA). A 100 μL plasma 
sample was mixed with 10 μL internal standard working 
solution and 300 μL acetonitrile. After centrifugation, 3 μL 
of supernatant was injected into the column. The lower limit 
of quantification was 1.0 ng/mL. The calibration curve was 
linear over the concentration range of 1.0–2,000 ng/mL. 
The precision of the assay was less than 2.7% coefficient of 
variation, and the accuracy of the assay was within the range 
of 93.7%–113.0%.
Measurements of ceTP activity
Plasma CETP activity was measured by using a fluorescent 
assay that was performed in microplates by using CETP activity 
assay kit (RB-EVAK; Roar Biomedical, New York, NY, USA). 
The CETP activity assay kit uses a donor molecule containing a 
fluorescent self-quenched neutral lipid that is transferred to an 
acceptor molecule in the presence of CETP. CETP-mediated 
transfer of the fluorescent neutral lipid to the acceptor molecule 
results in an increase in fluorescence (Excitation/Emission: 
465/535 nm). Prepared the 87 μL of Ex Vivo Kit Reagent A per 
373 μL of Ex Vivo Kit Reagent B to make Reagent C. Pipetted 
100 μL of plasma samples into the wells of a black microtiter 
plate and added 5 μL of Reagent C to each well of the microplate 
containing plasma samples. Incubated the microplates for 90 
minutes at 37°C and read the fluorescence intensity (excitation, 
465 nm; emission, 535 nm) using FlexStation® 3 (Molecular 
Devices, Sunnyvale, CA, USA).
Pharmacokinetic analysis
The PK parameters of CKD-519 were calculated by non-
compartmental analysis using Phoenix 64 WinNonlin 6.3 
(Pharsight, Mountain View, CA, USA). The maximum 
plasma concentration (C
max
) and the time to reach the C
max
 
(t
max
) were determined directly from the observed data. The 
area under the plasma concentration–time curve from 0 to last 
time (AUC
last
) was calculated using a linear trapezoidal rule. 
The terminal elimination rate constant (k
e
) was estimated by 
log-linear regression analysis. The elimination half-life (t
1/2
) 
and the apparent plasma clearance (CL/F) were calculated 
from the equations t
1/2
= ln(2)/k
e
 and CL/F = dose/AUC, 
respectively. AUC from 0 to infinity (AUC
inf
) was obtained 
by summation of AUC
last
 and C
last
/k
e
. The apparent volume 
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of distribution (Vd/F) was calculated from the equation, 
Vd/F = Dose/(k
e
⋅AUC
inf
).
Pharmacokinetic/pharmacodynamic 
(ceTP) analysis
The PK/PD relationship of CKD-519 was analyzed using 
NONMEM version 7.3 (Icon Development Solutions, Ellicott 
City, MD, USA) with the GFORTRAN compiler. The PK 
and PD parameters were estimated by first-order conditional 
estimation with interaction method. Various goodness-of-
fit criteria such as visual comparison of diagnostic scatter 
plot, likelihood ratio tests, measures of model stability and 
adequacy by condition number, significant digits, matrix 
singularity, and successful convergence were applied to 
select the most appropriate model. The linkage of PK and PD 
model was performed in a sequential manner that individual 
PK parameters estimated from the final PK model were fixed 
and added to the PD dataset.
statistical analysis
The PK data were described as the mean ± standard devia-
tion (SD) in each dose group except t
max
, which was presented 
as median (range). In addition, the dose proportionality 
of PK parameters (C
max
, AUC) was evaluated using the 
power model as follows: Ln(y) = α + β*Ln[Dose].22 The 
equivalent limits (L, U) were derived from the following 
formulas: L =1+ Ln(θ
L
)/Ln(r), U =1+ Ln(θ
H
)/Ln(r), where r 
is the ratio between the highest and lowest drug dose (r=16), 
and 0.8 and 1.25 were used for θ
L
 and θ
H
, respectively, 
based on the bioequivalence limits defined in the US Food 
and Drug Administration guidance. If the calculated 90% 
confidence interval (CI) for β (slope) was included within 
the predefined equivalent limits (L, U), dose proportionality 
was declared.
Demographic characteristics were analyzed using the 
Kruskal–Wallis test for comparison among the five cohorts. 
All analyses were conducted using SAS statistical software 
version 9.2 (SAS Institute Inc. Cary, NC, USA). All statistical 
tests were two-sided, and statistical significance was defined 
as P#0.05.
Results
study participants
A total of 40 healthy male individuals were enrolled and com-
pleted the trial. Eight participants were included in each dose 
group (25, 50, 100, 200, and 400 mg) and randomly assigned 
to active drug (CETP inhibitor, n=6) or placebo (n=2). There 
were no statistical differences in age, body weight, or height 
among the dose groups (P.0.05, Table 1).
Pharmacokinetics
The mean plasma CKD-519 concentration versus time profile 
after administration of single oral doses of CKD-519 from 
25 mg to 400 mg is shown in Figure 2. The calculated PK 
parameters are exhibited in Table 2. T
max
 was similar regard-
less of the dose group, with a median of 5–6 h. C
max
 and AUC 
increased with the dose; however, C
max
 and AUC normalized 
by dose decreased with each incremental dose. The terminal 
elimination phase was relatively long (39.6–70.4 h).
Dose proportionality of PK parameters, C
max
 and AUC, 
was analyzed with the power model. β values and 90% CI 
of C
max
 and AUC were out of range (β values [90% CI] for 
C
max
, 0.46 [0.28–0.63]; for AUC
last
, 0.49 [0.35–0.63]; for 
AUC
inf
, 0.50 [0.35–0.65]; acceptable range for β values, 
0.92–1.08).
Pharmacodynamics
The mean serum CETP activity versus time profile after 
administration of single oral doses of CKD-519 is shown in 
Figure 3. The inhibitory effect of CKD-519 on CETP activity 
increased with the ascending dose. The maximum inhibition 
of CETP activity by CKD-519 was observed at 6.3–8.3 h 
post-dose with approximately 65.4%–83.0% decrease from 
baseline: 65.4% (8.0 h) for 25 mg, 66.9% (6.3 h) for 50 mg, 
Table 1 Demographic characteristics of the study population
Characteristics 25 mg 
CKD-519
50 mg 
CKD-519
100 mg 
CKD-519
200 mg 
CKD-519
400 mg
CKD-519
Placebo Total P-valuea
(n=6) (n=6) (n=6) (n=6) (n=6) (n=10) (n=40)
age (years) 27.5±2.9 26.8±6.0 23.8±2.9 25.2±6.7 29.2±7.0 23.4±3.2 25.7±5.1 0.143
(24.0–30.0) (19.0–37.0) (19.0–28.0) (20.0–38.0) (19.0–40.0) (19.0–28.0) (19.0–40.0)
Body weight (kg) 69.3±4.7 63.5±6.9 71.9±3.0 68.9±4.3 69.6±5.3 68.9±6.9 68.7±5.7 0.189
(65.8–78.4) (56.6–76.5) (68.1–75.4) (65.0–77.2) (63.9–76.8) (58.6–80.0) (56.6–80.0)
height (cm) 173.1±4.9 172.6±4.8 176.9±6.7 173.3±3.6 174.2±4.9 174.6±4.2 174.2±4.7 0.848
(167.5–179.5) (165.7–177.7) (168.3–184.3) (167.8–177.3) (166.3–178.4) (167.4–181.5) (165.7–184.3)
Notes: Data are expressed as the mean ± standard deviation (minimum–maximum). aP-values among the six groups were calculated using the Kruskal–Wallis test.
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Figure 2 Mean plasma CKD-519 concentration–time profiles after administration of ascending single oral doses in healthy male subjects.
Notes: (A) linear scale; (B) semi-logarithmic scale. error bars denote standard deviations.
Table 2 summary of pharmacokinetic parameters for cKD-519 after administration of single oral dose in healthy volunteers
PK parameters 25 mg CKD-519 50 mg CKD-519 100 mg CKD-519 200 mg CKD-519 400 mg CKD-519
(n=6) (n=6) (n=6) (n=6) (n=6)
cmax (ng/ml) 89.5±63.1 157.1±84.1 184.2±91.6 241.3±105.9 281.1±78.4
cmax, dn (μg/ml) 3.6±2.5 3.1±1.7 1.8±0.9 1.2±0.5 0.7±0.2
aUclast (ng⋅h/ml) 914.8±510.1 1,623.2±776.8 1,935.0±836.3 2,827.3±1,226.7 3,292.6±695.3
aUclast, dn (μg⋅h/ml) 36.6±20.4 32.5±15.5 19.4±8.4 14.1±6.1 8.2±1.7
aUcinf (ng⋅h/ml) 989.4±563.7 1,814.8±897.7 2,164.5±931.4 3,045.4±1,273.7 3,732.0±1,013.9
aUcinf, dn (μg⋅h/ml) 39.6±22.6 36.3±18.0 21.7±9.3 15.2±6.4 9.3±2.5
t1/2 (h) 39.6±30.6 52.0±14.6 66.9±18.7 53.2±8.0 70.4±30.9
tmax (h) 5.0 (5.0–6.0) 5.0 (5.0–6.0) 6.0 (5.0–6.0) 6.0 (5.0–6.0) 6.0 (5.0–6.0)
cl/F (l/h) 34.2±21.0 36.0±21.8 54.9±26.2 75.1±28.9 113.1±26.7
Vd/F (l) 1,370.0±475.6 2,456.3±1,055.4 5,024.4±2,137.1 5,691.0±1,947.4 10,735.8±2,334.1
Note: Values are presented as mean ± standard deviation, except for tmax, which is presented as median (minimum–maximum).
Abbreviations: aUclast, area under the plasma concentration–time curve from dosing time (0 h) to the time of the last measurable concentration; aUcinf, aUc from time 
0 h extrapolated to infinity; Cmax, maximum plasma concentration of drug; cl/F, apparent total clearance; dn, dose normalized; PK, pharmacokinetic; t1/2, terminal elimination 
half-life; tmax, time to cmax; Vd/F, apparent volume of distribution.
78.3% (8.3 h) for 100 mg, 80.7% (7.0 h) for 200 mg and 
83.0% (7.3 h) for 400 mg. The relationship between plasma 
concentrations of CKD-519 and inhibition of serum CETP 
activity is exhibited in Figure 4. There was no hysteresis in 
the relationship (data not shown), and it was best described 
using a sigmoid E
max
 model. The half-maximal effective 
concentration (EC
50
) was 17.3 ng/mL.
safety
There were 13 AEs in total (two cases for 25 mg group: 
headache, hypertriglyceridemia; three cases for 50 mg 
group: diarrhea, nausea, dizziness; one case for 100 mg 
group: creatine phosphokinase [CPK] increased; one case 
for 200 mg group: dyspepsia; two cases for 400 mg group: 
periodontal disease, allergic rhinitis; four cases for placebo 
group: headache, CPK increased, dyspnea, conjunctivitis). 
Among the AEs, three AEs (two events of CPK increased, 
one event of hypertriglyceridemia) were considered to be 
possibly related with the study drug. However, all AEs were 
of mild or moderate severity, and the subjects recovered 
without any sequelae or complications. There were no seri-
ous drug-induced AEs in this study. A repeated ANOVA 
found no significant differences in SBP and DBP between 
the dose groups (Figure 5). In addition, there were no clini-
cally meaningful changes in physical examinations and ECG 
(data not shown).
Discussion
This is the first clinical study in humans to evaluate the PK, 
PD and safety of CKD-519, a new CETP inhibitor. Based 
on the results, CKD-519 exhibits potent CETP inhibitory 
action and is tolerable without any significant AEs, including 
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increase in blood pressure. In addition, it has PK and PD 
profiles appropriate for once-daily dosing regimen.
CKD-519 exhibited biphasic elimination with long terminal 
t
1/2
 (39.6–70.4 h). Most of its exposure showed within 48 h 
after oral administration in fasted state, followed by a slow 
and flat terminal elimination phase. CKD-519 has neutral 
lipophilic properties (LogD is 7.4, and LogP is .5.0 at pH 
7.4), which explains its high affinity and accumulation in 
adipose tissue (Chong Kun Dang Pharmaceutical Corp., 
unpublished data, 2015). After single intravenous CKD-
519 administration in rat, hamster, and monkey, the Vd 
was equal to 0.99–1.11 L/kg in all animals (Chong Kun 
Dang Pharmaceutical Corp., unpublished data, 2015). The 
Vd/F in this study was higher than the Vd of animal, and 
it showed a tendency to increase with the dose after being 
normalized with each participant’s body weight: 19.8 L/kg 
for 25 mg group, 38.7 L/kg for 50 mg group, 69.9 L/kg for 
100 mg group, 82.6 L/kg for 200 mg group, and 154.3 L/kg 
for 400 mg group. This property of CKD-519 might be the 
reason for its long terminal t
1/2
 in plasma.
The C
max
 and AUC increased with dose, but the increase 
was less than proportional. In fact, CKD-519 exposure 
when normalized to dose decreased with dose. This can 
be explained by the in vivo data that CKD-519 has decreased 
bioavailability at higher doses (Chong Kun Dang Pharma-
ceutical Corp., unpub lished data, 2015). In vitro studies 
revealed that transport-mediated uptake did not play a role 
in CKD-519 absorption, and the solubility of CKD-519 in 
gastrointestinal fluid was shown to be poor in animal studies 
(Chong Kun Dang Pharmaceutical Corp, unpublished data, 
2015). These data suggest that gastrointestinal absorption of 
CKD-519 in human may get saturated at high doses.
The inhibition of CETP activity by CKD-519 increased 
as the dose increased. In the dose range of 25–400 mg, 
the single oral administration of CKD-519 achieved a 
maximum decrease in CETP activity by 62%–83% from 
baseline at about 6.3–8.3 h after dosing. CKD-519 400 mg 
inhibited CETP activity by 43% at 24 h post-dose. Within 
the range between 25 mg and 100 mg of CKD-519, CETP 
activity decreased sharply with dose, but then it appeared 
that inhibition of CETP activity was reduced with higher 
doses (200 and 400 mg) of CKD-519, as C
max
 and AUC also 
showed similar pattern with ascending doses of CKD-519. 
The relationship between concentration of CKD-519 and 
CETP activity was best described as a sigmoid E
max
 model, 
with an EC
50
 of 17.3 ng/mL. Considering the PK and PD 
profiles of CKD-519, once-daily dosing regimen seems to 
be appropriate, and it is estimated that CKD-519 100 mg 
would be the most appropriate dose in an ensuing multiple 
doses study.
One of the main concerns in the development of CKD-519 
was a possibility of it having adverse effects on the change 
of SBP or DBP, because the first CETP inhibitor to be devel-
oped, namely torcetrapib, was withdrawn due to its unde-
sired effect on BP.9 Elevation of BP caused by torcetrapib 
was associated with a substantial increase of aldosterone, 
resulting in electrolyte changes and BP increase,16 which is 
considered an off-target effect related to the activation of 
mineralocorticoid receptor by aldosterone, irrespective of 
HDL-C increasing mechanism by CETP inhibitor.9 In this 
study, before investigating into a possible off-target effect of 
CKD-519, as described for torcetrapib, we first looked into 
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Figure 4 relationship between ceTP activity and cKD-519 concentration after 
administration of single oral doses of cKD-519 (from 25 mg to 400 mg) in healthy 
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baseline–time profiles after administration of ascending single oral doses in healthy 
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Note: Dashes mean baseline ceTP activity.
Abbreviation: ceTP, cholesteryl ester transfer protein.
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the possibility if CKD-519 may have an effect on BP. There 
were no significant differences found between baseline and 
post-dose SBP and DBP in all dose groups, and between 
placebo and CKD-519 groups.
Furthermore, CKD-519 was well tolerated within the 
dose range of 25–400 mg by all the participants throughout 
the study. There were no clinically significant changes in 
physical examinations findings and ECG. The AEs observed 
in the subjects who received CKD-519 were similar to those 
observed in the subjects who received placebo, and there 
were no serious AEs.
In this study, we investigated the safety, PK, and PD of 
CKD-519 administered for the first time in humans. With 
regard to an apparently long terminal t
1/2
 and PK profiles 
suggestive of saturable absorption, we can possibly consider 
saturable absorption or distribution of the drug into adipose 
tissue. However, to better understand these PK profiles of 
CKD-519, other studies about absorption or disposition of 
CKD-519 in humans are necessary. Even though the results 
showed no undesirable effect on BP, it would be prudent 
to monitor BP closely in the subsequent studies of multiple 
doses, especially in patients with dyslipidemia. Evaluation 
of aldosterone, cortisol or intensive BP monitoring may be 
warranted to completely exclude a possibility of indirect 
effects of CETP inhibition on adrenal hormones, since 
adrenal gland requires cholesterol for the biosynthesis of 
mineralocorticoids and glucocorticoids, and human cells 
possess both scavenger receptor-BI and LDL receptors.23 
Furthermore, the results of this study cannot be generalized 
to patients with dyslipidemia because this study evaluated 
only healthy individuals. In order to determine the safety of 
CKD-519, the study needs to be conducted in patients with 
dyslipidemia. Although there may be some limitations to the 
study, the results of this study, especially overall safety and 
tolerability as well as PD data showing clinical evidence of 
CETP inhibition, provide reasonable ground that enables 
further development of the drug.
Conclusion
Single doses of CKD-519 ranging from 25 mg to 400 mg 
administered to healthy individuals were well tolerated with 
no serious or severe AEs, and showed potent inhibition of 
CETP activity (maximum 83% at 400 mg dose). Therefore, 
CKD-519 is a safe and potent CETP inhibitor that can be 
administered once daily.
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